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Background
Bipolar disorder is a life-long psychiatric illness found in
2-5% of the population [1]. The aim of the present study
was to describe the 12-week (acute phase) clinical out-
comes of Greek standard practice in the pharmacological
treatment of acute mania.
Materials and methods
EMBLEM (European Mania in Bipolar Evaluation of Med-
ication) was a 2-year prospective observational study on
the outcomes of pharmacological treatment for acute
mania. All treatments were at the discretion of the treating
psychiatrist. The clinical status of the Greek patients was
studied during the first 12 weeks of treatment in the acute
phase of the illness, with the use of CGI-BP, YMRS and
HAM-D-5.
Results
A total of 3684 patients were enrolled in 14 European
countries, between December 2002 and June 2004. The
Greek subpopulation consisted of 645 eligible individuals
(18%). Greek patients experienced clinical improvement
as shown by the decrease in mean CGI-BP overall and
mania subscales, YMRS and 5 item HAM-D over 12 weeks
of the acute phase. 72% of the Greek patients had
improved (defined as the first decrease of a minimum of
2 points in CGI-BP overall at any time during acute phase)
and 31% had recovered (defined as a score of 2 or less on
CGI-BP overall in the last visit and the visit prior to last).
Compliance also improved as the percentage of patients
who almost always complied with medication increased
from 44% at baseline to 82% at week 12. The majority of
patients received atypical antipsychotics either as mono-
therapy or as combination therapy for the duration of
treatment.
Conclusions
This large observational study showed that most patients
experienced clinical improvement after 12 weeks of treat-
ment and that atypical antipsychotics were the most com-
monly taken as combination therapy for acute mania.
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